Otros idiomas Dermata Therapeutics, Inc.

Acciones

DRMA

US2498453065

Mercado cerrado - Nasdaq Otros sitios de cotización 22:30:00 26/04/2024			Varia. Cinco días.	Varia. 1 de enero.
0,3427 ^USD	+0,76 %		+6,73 %	-43,82 %

21/03	Dermata Therapeutics, Inc. informa de los resultados del ejercicio finalizado el 31 de diciembre de 2023	CI
05/01	Wall Street se prepara para abrir a la baja ante unos datos mensuales de empleo mucho más fuertes de lo esperado	MT

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Dermata Therapeutics : Provides Corporate Update and Reports Full Year 2023 Financial Results - Form 8-K	21/03
Dermata Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03
Dermata to Present at the Emerging Growth Conference on February 7, 2024	02/02
Wall Street Set to Open Lower as Monthly Jobs Data Much Stronger Than Expected	05/01
Investors Await Jobs Data as US Futures Trend Lower in Friday's Premarket	05/01
Top Premarket Gainers	05/01
North American Morning Briefing : Bond Yields Rise Again as Jobs Data Loom	05/01
Dermata Therapeutics, Inc. Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne	20/12
Dermata to Begin Enrolling Patients in DMT310 Phase 3 Acne Clinical Program in December 2023 based on Agreement with FDA on the Phase 3 Protocols	17/11
Sector Update: Health Care Stocks Slightly Advancing Late Afternoon	16/11
Dermata Therapeutics to Begin Enrolling Patients in Acne Drug Study; To Raise $2.3 Million	16/11
Dermata Therapeutics, Inc. to Begin Enrolling Patients in DMT310 Phase 3 Acne Clinical Program in December 2023 Based on Agreement with FDA on the Phase 3 Protocols	16/11
Dermata Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11
Dermata Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/08/23
Dermata Therapeutics, Inc. Announces Positive Feedback from FDA on the DMT310 Phase 3 Clinical Development Program in Moderate-To-Severe Acne	27/06/23
Dermata Therapeutics, Inc. Announces Positive Results from its DMT310 Phase 2b Study of Its Once-Weekly Topical Treatment in Patients with Moderate-To-Severe Acne Vivis	08/06/23
Dermata Therapeutics Completes $1.8 Million Share Offering	26/05/23
DERMATA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	24/05/23
Certain Warrants of Dermata Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 16-MAY-2023.	16/05/23
Certain Common Stock of Dermata Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 16-MAY-2023.	16/05/23

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Dermata Therapeutics, Inc.

Acciones

DRMA

US2498453065

Otros idiomas

Filtros